SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (295)12/11/2007 5:11:04 PM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 684
 
Eyeballing the list from November it looks like strong bounces in NUVO and ADLR, nothing else too notable.

All NUVO has done lately is present the data from the (failed) phase-3 catheter-occlusion trial at ASH, and the top-line data from this trial were reported many months ago.

If investors are thinking more positively about Alfimeprase in light of the ASH presentation, I’m not sure exactly why.



To: rkrw who wrote (295)12/13/2007 11:27:10 AM
From: rkrw  Respond to of 684
 
NBIX crunched today, now below 9/30 cash, when factoring in the $20M upfront from the Japan deal and $60M from their building sale.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News